Six monthly intravenous zoledronic acid in childhood osteoporosis

Munns, Craig F; Hl, Ooi; Briody, JN; Cowell, CT

doi:10.1186/1687-9856-2013-s1-p164

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More recently, shorter, as well as low-dose pamidronate, protocols (97,98) have been used, in particular, BPs such as neridronate and zoledronate, which have the benefit of higher potency and less frequent administration compared to pamidronate. Intravenous infusions of zoledronate (0.025-0.05 mg/kg per day, commonly given over 30 min as a single dose, every 6 months) are associated with improvement in bone mass and subsequent reduction in fracture risk (99,100,101,102). Similarly, intravenous neridronate (2mg/kg per day over 30 min every 6 months) improves BMD and reduces fracture rates (89,103).…”

Section: Bp Therapymentioning

confidence: 99%

ENDOCRINOLOGY AND ADOLESCENCE: Osteoporosis in children: diagnosis and management

Saraff

Högler

2015

European Journal of Endocrinology

View full text Add to dashboard Cite

Osteoporosis in children can be primary or secondary due to chronic disease. Awareness among paediatricians is vital to identify patients at risk of developing osteoporosis. Previous fractures and backaches are clinical predictors, and low cortical thickness and low bone density are radiological predictors of fractures. Osteogenesis Imperfecta (OI) is a rare disease and should be managed in tertiary paediatric units with the necessary multidisciplinary expertise. Modern OI management focuses on functional outcomes rather than just improving bone mineral density. While therapy for OI has improved tremendously over the last few decades, this chronic genetic condition has some unpreventable, poorly treatable and disabling complications. In children at risk of secondary osteoporosis, a high degree of suspicion needs to be exercised. In affected children, further weakening of bone should be avoided by minimising exposure to osteotoxic medication and optimising nutrition including calcium and vitamin D. Early intervention is paramount. However, it is important to identify patient groups in whom spontaneous vertebral reshaping and resolution of symptoms occur to avoid unnecessary treatment. Bisphosphonate therapy remains the pharmacological treatment of choice in both primary and secondary osteoporosis in children, despite limited evidence for its use in the latter. The duration and intensity of treatment remain a concern for longterm safety. Various new potent antiresorptive agents are being studied, but more urgently required are studies using anabolic medications that stimulate bone formation. More research is required to bridge the gaps in the evidence for management of paediatric osteoporosis.

show abstract

Section: Bp Therapymentioning

confidence: 99%

ENDOCRINOLOGY AND ADOLESCENCE: Osteoporosis in children: diagnosis and management

Saraff

Högler

2015

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Intravenous bisphosphonates reduce serum calcium concentrations after the first infusion cycle [57].…”

Section: Biphosphonatesmentioning

confidence: 99%

“…Vitamin D/calcium [42][43][44][45][46][47] Not recommended therapies Bisphosphonates [48][49][50][51][52][53][54][55][56][57][58][59][60][61][62][63] New therapies Teriparatide [64][65][66][67][68][69][70] GnRh [71] GnRh + oxandrolone [72][73][74][75][76][77][78][79][80][81][82][83][84][85][86][87][88] Denosumab [90] Anti-DKK1 [91] Anti-sclerostin [94,95] Romosozumab [93]…”

Section: Recommended Therapiesmentioning

confidence: 99%